You are viewing the site in preview mode

Skip to main content

Advertisement

Fig. 2 | Journal for ImmunoTherapy of Cancer

Fig. 2

From: Outcomes of vedolizumab therapy in patients with immune checkpoint inhibitor–induced colitis: a multi-center study

Fig. 2

Representative endoscopic and histologic findings before and after vedolizumab treatment in patients who failed treatment. (a, b) Endoscopic presentation before vedolizumab therapy showing diffuse erythema, edema and mucosal ulcerations. (c, d) Endoscopic presentation from the same patients after vedolizumab therapy showing persistence of mucosal ulceration and erythema. (e) Before vedolizumab therapy, chronic active colitis with basal plasmacytosis and expansion of lamina propria by lymphohistiocytes. In the top right corner, there are focal areas of neutrophil infiltration in the crypt lumen forming cryptitis and crypt abscess. (f) After vedolizumab therapy, chronic active colitis with basal plasmacytosis and Paneth cell metaplasia. In the top right corner, there are focal areas of active colitis with focal ulceration and granulation tissue

Back to article page